hero image

Biogen to Participate at World Medical Innovation Forum Virtual Gathering: COVID-19 on May 11, 2020

May 8, 2020

Cambridge, Mass. – May 8, 2020 – Biogen (Nasdaq: BIIB) today announced that its Chief Executive Officer Michel Vounatsos will participate in a fireside chat at the upcoming World Medical Innovation Forum Virtual Gathering: COVID-19.

  • Monday, May 11, 2020, 1:45-2:05 p.m. ET – Keeping Priority on the Biggest Diseases, Michel Vounatsos, Chief Executive Officer, Biogen, moderated by Jean-François Formela, MD, Partner, Atlas Venture

This fireside chat will discuss how Biogen is tackling some of society’s most devastating neurological and neurodegenerative disorders and share perspective on the impact the global COVID-19 pandemic is having on the biopharmaceutical industry.

To access the fireside chat, please complete a free registration at worldmedicalinnovation.org in advance of the meeting. Following the event, an archived version will be available on the Investors section of Biogen’s website at investors.biogen.com.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.

Biogen Safe Harbor

This fireside chat will include forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our strategy and plans; potential of our commercial business and pipeline programs; the prospects of our product portfolio; pipeline potential and progress; anticipated clinical trials and data readouts; the potential benefits, safety, and efficacy of our products and investigational therapies; and regulatory filings, product launches, and the timing thereof. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including the risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date they are made. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.

Media Contact: Investor Contact:
David Caouette Joe Mara
+1 617 679 4945 +1 781 464 2442
public.affairs@biogen.com  IR@biogen.com


July 29, 2021
Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

July 29, 2021
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice ICARE AD-US is one of three programs to generate post-approval data on ADUHELM, including the re-dosing Phase 3b EMBARK study and the planned confirmatory Phase